Clinical Trial Update: Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the efficacy and safety of cemiplimab as a first-line treatment for patients with advanced basal cell carcinoma and is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Basal Cell Carcinoma (BCC), First Line Treatment | Phase 2 | Status: RECRUITING